2024
Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon‐HP trial
Chey W, Mégraud F, Laine L, Smith N, Leifke E, Hunt B, Howden C. Influence of patient characteristics on Helicobacter pylori eradication with Vonoprazan: A subgroup analysis of the pHalcon‐HP trial. JGH Open 2024, 8: e70044. PMID: 39554983, PMCID: PMC11567116, DOI: 10.1002/jgh3.70044.Peer-Reviewed Original Research
2010
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies
Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies. Alimentary Pharmacology & Therapeutics 2010, 33: 203-212. PMID: 21114792, DOI: 10.1111/j.1365-2036.2010.04516.x.Peer-Reviewed Original ResearchConceptsHeartburn resolutionErosive oesophagitisExtended releaseLA grade CSevere erosive oesophagitisDouble-blind trialDouble-blind studyPossibility of benefitCurrent PPIsD oesophagitisSevere oesophagitisGERD patientsSecondary endpointsPrimary endpointSymptomatic resolutionAcid suppressionSubgroup analysisDrug exposureClinical trialsOesophagitisGrade DGrade CFurther evaluationEsomeprazoleAcid inhibition